AMRN

@Amarincorp

Amarin Corporation plc is a biopharmaceutical company focused on therapeutics to improve cardiovascular health.

Dublin, Ireland
Vrijeme pridruživanja: studeni 2014.

Tweetovi

Blokirali ste korisnika/cu @Amarincorp

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @Amarincorp

  1. 13. sij

    Amarin has launched – a campaign to educate people on how they can better protect themselves against persistent risk. 1 in 3 American adults are living with some form of disease. Learn more:

    Poništi
  2. 3. sij

    Wonderful start to 2020! AHA tout's Amarin's REDUCE-IT as one of the "Top Heart Disease and Stroke Research Advances in 2019." Second year in a row for REDUCE-IT. .

    Poništi
  3. 2. sij

    More good news for patients. Canada approves Vascepa. Congrats to our partner HLS Therapeutics, . .

    Poništi
  4. 13. pro 2019.

    New FDA approval of Amarin’s drug is first-ever approved for such indication.

    Poništi
  5. 11. pro 2019.

    Proud to have our landmark study, REDUCE-IT®, recognized as one of the most important advances in preventative cardiology during the past decade!

    Poništi
  6. 18. stu 2019.

    Amarin salutes for continuing the dialogue on improving CV Health. We were proud to be part of the conversation. ,

    Poništi
  7. 18. stu 2019.

    "The award is a tribute to the significant pioneering progress made by Amarin’s dedicated employees in advancing cost-effective preventative care solutions for reducing the risk of cardiovascular disease," says John Thero, President and CEO.

    Poništi
  8. 14. stu 2019.

    FDA’s Endocrinologic and Metabolic Drugs Advisory Committee recommends approval for expanded use of Amarin’s therapy. Read more here:

    Poništi
  9. 13. stu 2019.

    Tune in, , as Dr. Bhatt leads a discussion on emerging treatment approaches for reducing cardiovascular risk. ,

    Poništi
  10. 13. stu 2019.

    The estimates the cost of treating will exceed $1 trillion by 2035. Amarin CEO John Thero provides insight into how we can reverse this trend, save lives & reduce the tremendous burden on families & our economy:

    Poništi
  11. 12. stu 2019.

    Amarin is proud to support the discussion on urgent challenges in cardiovascular disease.

    Poništi
  12. 5. stu 2019.

    Amarin’s growth was again positive in Q3. We reported record revenue levels, positive cash flow and a strong financial position while adding to the breadth, depth and experience of our commercial organization. See Q3 press release, .

    Poništi
  13. 4. stu 2019.

    Hello Philly! Amarin is back at the American Heart Association Scientific Sessions, , 11/16-18 – sharing more data on icosapent ethyl (Vascepa®) and cardiovascular disease. , ,

    Poništi
  14. 16. ruj 2019.

    Residual cardiovascular risk in patients on statins remains an important unmet medical issue. @NLA issued an important statement on addressing. Check out Amarin's press release . ,

    Poništi
  15. proslijedio/la je Tweet

    IMPORTANT UPDATE: accredited program: The Evolving Landscape of Triglyceride Lowering and Cardiovascular Outcomes: Clinical Pearls and Patient Application, Friday, 9/13, 7-9 PM featuring Dr. Ann C. Skulas-Ray, Dr. James Underberg, and Dr. Kevin C. Maki.

    Poništi
  16. 13. ruj 2019.

    AMARIN consolidates U.S. presence into new offices, , supporting further growth!

    Poništi
  17. 3. ruj 2019.

    Check out Amarin’s press release on the new 2019 updates to the ECS/EAS updated clinical practice guidelines for dyslipidaemias. Read more here

    Poništi
  18. 2. ruj 2019.

    Strong interest in Medscape Live satellite symposium @ on treating CVD with omega-3 fatty acids (Bhatt, Weintraub, Mason).

    Poništi
  19. 1. ruj 2019.

    Our team is at in Paris and looking forward to discussing global cardiovascular health with HCPs committed to

    Poništi
  20. 31. kol 2019.

    : there are new scientific guidelines about treating cardiovascular risks, including elevated triglycerides, diabetes, and LDL-cholesterol?

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·